<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 27, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843726</url>
  </required_header>
  <id_info>
    <org_study_id>I 124407</org_study_id>
    <secondary_id>I 124407</secondary_id>
    <nct_id>NCT00843726</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients With Node Negative, Peripheral Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the&#xD;
      tumor and cause less damage to normal tissue. It is not yet known which regimen of radiation&#xD;
      therapy is more effective in treating patients with non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy&#xD;
      regimens and to see how well they work in treating patients with stage I or stage II&#xD;
      non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the incidence of toxicity with two established stereotactic body radiotherapy&#xD;
           (SBRT) regimens in patients with node-negative, peripheral stage I or II non-small cell&#xD;
           lung cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare quality of life, patterns of failure, disease-free survival, and overall&#xD;
           survival of these patients after treatment with one of two established SBRT regimens.&#xD;
&#xD;
        -  To correlate outcomes and toxicities with imaging and patient and tumor biomarkers.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to Karnofsky performance status and treatment&#xD;
      center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).&#xD;
&#xD;
        -  Arm II: Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.&#xD;
&#xD;
      Quality of life is assessed periodically by the EORTC QLQ-C30 and -LC13 questionnaires&#xD;
&#xD;
      Blood and tissue samples may be collected periodically and examined for biomarkers via ELISA&#xD;
      and immunoblotting.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2008</start_date>
  <completion_date type="Actual">May 6, 2020</completion_date>
  <primary_completion_date type="Actual">May 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of RTOG grade 3 or higher toxicity</measure>
    <time_frame>1year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between blood and serum markers and survival and toxicity</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <description>Patients undergo 1 or 3 high-dose fractions</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer&#xD;
&#xD;
          -  T1-T2, N0 disease measuring â‰¤ 5 cm( T3 tumor based on chest wall involvement is&#xD;
             Excluded)&#xD;
&#xD;
          -  Surgically resectable primary disease, however patient evaluated by thoracic&#xD;
             oncologist and deemed medically inoperable OR patient refuses surgical resection&#xD;
&#xD;
          -  Age &gt;= 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior thoracic radiation therapy&#xD;
&#xD;
          -  T2 or T3 tumor greater than 5 cm or T3 tumor based on chest wall involvement&#xD;
&#xD;
          -  Node positive or metastatic disease&#xD;
&#xD;
          -  Tumor location within the zone of the proximal bronchial tree. The proximal bronchial&#xD;
             tree is defined as the carina, right and left main bronchi, right and left upper lobe&#xD;
             bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, and&#xD;
             right and left lower lobe bronchi. The zone of the proximal bronchial tree is defined&#xD;
             as a volume 2cm in all directions around the proximal bronchial tree.&#xD;
&#xD;
          -  No other conditions deemed by the PI or associates to make the patient ineligible for&#xD;
             protocol investigations, procedures, and high-dose external beam radiotherapy (e.g.,&#xD;
             unable to lie still and breathe reproducibly)&#xD;
&#xD;
          -  Pregnant or unwilling to use adequate contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anurag K. Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 15, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

